The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
Atul DeodharDafna D GladmanRebecca BolceDavid SandovalSo Young ParkSoyi Liu LeagePeter NashDenis PoddubnyyPublished in: Therapeutic advances in musculoskeletal disease (2023)
IXE is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.